SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan” (“i2.JP”; Website: https://www.i2jp.net/en/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
Contacts
Lightnix Inc.
Akihiro ISUMI, General Manager
+81-48-951-3637
info@lightnix.jp
https://www.lightnix.jp/en/
Key takeaways:The NSW Blues named seven changes for their Australia One-Day Cup clash with Western…
Key takeaways:Tim David has been named for Tasmania in a push for a 2027 ODI…
Key takeaways:The IMD issued a critical alert warning of an extremely dangerous 24-hour period for…
Key takeaways:The Bucks vs Bulls game is set for a 3:00 PM CT start time,…
Key takeaways:MSG staff received a phishing email tied to New York Knicks championship rings, and…
Key takeaways:The Real Madrid vs Barcelona fixture is being presented as the first Clásico at…